Long-Term Outcomes Similar With LDG and ODG in Locally Advanced Gastric Cancer
The 5-year overall survival rates were similar.
Diagnosis & Disease Information
Robotic Gastrectomy for Gastric Cancer Does Not Cut Postop Infections
The overall incidence of postoperative complications was significantly lower with robotic versus laparoscopic gastrectomy.
Study Identifies Molecular Determinants of Gastric/Gastroesophageal Junction Cancer
For the exploratory analysis, researchers used whole-exome sequencing data from the KEYNOTE-061 trial.
Data Support Nivolumab Plus Chemo as Standard First-Line Therapy for Advanced Gastric, Esophageal Cancers
Nivolumab plus chemotherapy improved overall survival.
Trifluridine/Tipiracil Combination Effective in Third and Later-Line Metastatic Gastric Cancer
This exploratory subgroup analysis of the TAGS study assessed the efficacy, safety, and quality of life (QOL) results observed in patients who received trifluridine/tipiracil or placebo in the third- or later-line settings.
Pembrolizumab Triplet Exhibits Efficacy in HER2-Positive Advanced Gastric, GEJ Cancer Independently of PD-L1 Status
Investigators of the phase 1b/2 PANTHERA trial presented updated clinical and molecular profiling data from 43 patients who received frontline pembrolizumab, trastuzumab, and chemotherapy.
First-Line Nivolumab Plus Chemotherapy Improves Survival in Gastric, Gastroesophageal Junction, and Esophageal Cancers
Nivolumab plus chemotherapy prolonged survival of patients with advanced gastric, gastroesophageal junction, and esophageal cancers compared with chemotherapy.
Analysis of Ramucirumab Suggests Risks Outweigh Benefits
A meta-analysis of randomized controlled trials found that there are significant risks for severe or fatal adverse events with ramucirumab, with only modest improvements in OS or PFS.
Antibody-Drug Conjugate for Advanced HER2-Positive Gastric Cancer Improves Outcomes
T-DXd treatment was associated with a better ORR and prolonged OS compared with standard chemotherapy with either irinotecan or paclitaxel.
3 Years of Adjuvant Imatinib Improves Long-Term Overall Survival in Gastrointestinal Stromal Tumor
Adjuvant treatment of GIST with imatinib for 36 months prolonged OS and RFS compared with 12 months of imatinib, according to data from nearly 10 years of follow-up.
- Loading...
Loading...
Next post in ASCO 2020
Loading... 
Loading...